regorafenib Articles

News briefs from Sanofi, Bayer, GlaxoSmithKline and Novartis

21 December 2012

Bayer's regorafenib overcomes resistance in patients with rare sarcoma

22 November 2012

Bayer's Stivarga races to FDA approval on the heels of Zaltrap

7 October 2012

Early FDA approval for Bayer's Stivarga in advanced colorectal cancer

28 September 2012

Bayer's regorafenib gets priority review for CRC in Japan

13 September 2012

Bayer files NDA for regorafenib for the treatment of GIST

31 August 2012

News briefs: US priority review for regorafenib; Ph IIb blisibimod data

29 June 2012

More news from ASCO meeting

5 June 2012

News briefs: GlaxoSmithKline and Bayer

24 May 2012

Bayer cancer drug candidate regorafenib improves survival in GIST

4 April 2012

Bayer’s Xarelto OKed in Japan; promising regorafenib data

19 January 2012

Bayer boasts four potential pipeline blockbusters

21 December 2011

Bayer halts regorafenib trial for colorectal cancer on good Ph III results

27 October 2011

Bayer settles with Onyx over Nexavar and regorafenib with $160 million payment

13 October 2011

US FDA licenses Sanofi Pasteur's Fluzone Intradermal; fast-tracks Bayer’s regorafenib

11 May 2011

Bayer gains US FDA approval for new combo oral contraceptive Natazia; enrolls Ph III regorafenib study in colorectal cancer

7 May 2010

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end